Barbara Armentrout
Acute Care · Richmond, VANPI 1902183700
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 251 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 33.5% of the total. Reporting peaked in 2023 at $1,523 and has fallen 67.2% since, to $499 in 2025. Among acute care clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 251 payments — averaging $15.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Pfizer$270
- Amgen$250
- Arbor Pharmaceuticals, Inc.$122
- Scilex Pharmaceuticals Inc.$110
- plus $648 from 13 others
What the payments were for
- Food & beverage$3,837100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 74 | $1,284 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 85 | $1,154 |
| Pfizer | 13 | $270 |
| Amgen | 21 | $250 |
| Arbor Pharmaceuticals, Inc. | 18 | $122 |
| Scilex Pharmaceuticals Inc. | 6 | $110 |
| Collegium Pharmaceutical, Inc. | 5 | $102 |
| Ardelyx, Inc. | 1 | $82 |
| Biodelivery Sciences International, Inc. | 5 | $73 |
| Impel Pharmaceuticals Inc. | 4 | $71 |
| Biohaven Pharmaceuticals, Inc. | 2 | $51 |
| IBSA Pharma Inc. | 2 | $43 |
| Tolmar, Inc. | 2 | $41 |
| Redhill Biopharma Inc. | 2 | $38 |
| GRT US Holding, Inc. | 5 | $37 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Hikma Pharmaceuticals USA | 2 | $31 |
| Upsher-smith Laboratories LLC | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$344
- QULIPTA$236
- NURTEC ODT$105
How this compares
$3,837 in reported general payments places this provider in the 90th percentile of 599 acute care providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PercocetOxycodone Hcl/Acetaminophen | 24 | $113,122 |
| UbrelvyUbrogepant | 66 | $102,778 |
| Xtampza ErOxycodone Myristate | 67 | $59,769 |
| QuliptaAtogepant | 41 | $48,009 |
| RelistorMethylnaltrexone Bromide | 20 | $45,317 |
| OxycontinOxycodone Hcl | 61 | $30,842 |
| Oxycodone Hcl | 558 | $15,923 |
| ZtlidoLidocaine | 19 | $12,951 |
| MovantikNaloxegol Oxalate | 29 | $11,754 |
| LinzessLinaclotide | 13 | $7,813 |
| Lidocaine | 41 | $7,198 |
| Morphine Sulfate ErMorphine Sulfate | 187 | $5,711 |
| Diclofenac Sodium | 57 | $5,507 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 158 | $5,031 |
| Naloxone Hcl | 59 | $3,971 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta, Linzess | $1,284 | $158,600120 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $102 | $59,76967 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $1,154 | $45,31720 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $110 | $12,95119 claims |
| Redhill Biopharma Inc.Movantik | $38 | $11,75429 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Morphine Sulfate | $31 | $2,26031 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 599 acute care providers in Virginia.
Other acute care in Richmond
- Rachel DukeRichmond$751K
- Mica FerlisRichmond$20K
- Jonathan PenderRichmond$13K
- Erin PerlmutterRichmond$13K
- Emily GilbertRichmond$10K
- Linda HazelgrenRichmond$9K
- Stephanie HerndonRichmond$9K
- Christine RobinsonRichmond$8K
- Kelly McAdamsRichmond$7K
- Linda KashiwabaraRichmond$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.